Loading...
XSWX
MMTX
Market cap2mUSD
Dec 12, Last price  
2.89CHF
Name

Relief Therapeutics Holding SA

Chart & Performance

D1W1MN
XSWX:MMTX chart
P/E
—
P/S
46.73
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.90%
Rev. gr., 5y
60.47%
Revenues
642k
-92.37%
14,827,00014,545,00013,740,000386,382034,932,00020,714,00019,490,000256,11715,0000565,000003,321,0006,081,0006,033,0008,417,000642,307
Net income
-10m
L-42.11%
-2,000,000-9,401,000-12,214,000-19,397,000-59,166,000-1,299,000-12,239,000-12,280,000-9,154,000-16,834,000-2,887,000-436,000-7,460,000-7,828,000-34,705,000-50,790,000-98,181,000-17,119,000-9,910,748
CFO
-7m
L+136.60%
-3,730,900-9,554,639-3,316,076-16,443,609-10,243,841-4,645,876000-2,888,000-1,173,000-618,000-728,000-18,254,000-35,718,000-24,126,000-17,612,000-2,916,000-6,899,305

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.
URL
https://relieftherapeutics.com/
IPO date
Sep 19, 2011
Employees
69
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT